INTRODUCTION {#S1}
============

*RGS1*, a member of the regulator of G-protein signaling (RGS) family^[@R1]^, has been associated with multiple immune mediated diseases^[@R2]--[@R5]^. Data from genome wide association studies show a significant association of SNPs in the *RGS1* region with multiple sclerosis and celiac disease^[@R2],[@R3]^ (P \< 10^−17^), and a suggestive association with type 1 diabetes^[@R4],[@R5]^. RGS proteins are GTPase activating proteins that modulate chemokine receptor signaling^[@R1]^. Chemokine receptors depend on heterotrimeric G-proteins to activate downstream effectors^[@R6]^. Upon ligand activation, the G-protein alpha subunit (Gα) exchanges GTP for GDP, resulting in dissociation from the Gβγ heterodimer^[@R7]^ and initiating signaling cascades that lead to cytoskeletal rearrangements and cell migration. Hydrolysis of GTP by Gα's intrinsic GTPase activity causes signal termination. This enzymatic activity is accelerated by RGS-family proteins^[@R1]^. *RGS1* is highly expressed in lymphoid organs and serves as a negative regulator of chemokine receptor signaling in lymphocytes^[@R1],[@R8]^. Ablation of *Rgs1* in mice was shown to modify B cell trafficking^[@R9]^. In addition, *Rgs1* deficiency leads to aberrant architecture of germinal centers^[@R9]--[@R11]^. Although the phenotype described for *Rgs1* knockout (KO) mice was largely attributed to B cell dysfunction, a subsequent study found that *Rgs1* also participates in chemotactic signaling in T cells^[@R12]^. *Rgs1* thus affects the migratory behavior of multiple cell types, and it is as yet unclear how *RGS1* gene variation modifies the risk of autoimmunity, and of type 1 diabetes in particular.

T follicular helper cells (T~FH~) reside in the follicular areas of secondary lymphoid organs where they promote B cells expansion and antibody affinity maturation within germinal centers^[@R13]^. T~FH~ maturation is a multistep process that begins in the T cell zone with the activation of naive CD4^+^ T lymphocytes and leads to expression of the transcription factor*Bcl6*. *Bcl6* drives the expression of the chemokine receptor CXCR5 that promotes migration from the T cell zone towards the B cell follicle^[@R14]^. This migration also requires downregulation of CCR7 signaling^[@R15]^. Of interest, *Rgs1* expression is markedly up-regulated in T~FH~ cells^[@R16]^, and this likely contributes to desensitizing migrating cells to CCR7 ligands. Notably, several studies have recently implicated T~FH~ cells in type 1 diabetes^[@R17]--[@R19]^. The frequency of T~FH~ cells was found to be elevated in patients with type 1 diabetes. A similar increase in T~FH~ cells was observed in a mouse model for autoimmune diabetes^[@R19]^.

To investigate a possible role for *RGS1* in autoimmunity, we developed inducible *Rgs1* knockdown (KD) mice within the nonobese diabetic (NOD) mouse model for type 1 diabetes^[@R20]^. *Rgs1* silencing recapitulated key phenotypes described for *Rgs1* KO mice^[@R9]^, including increased lymphocyte chemotaxis and enlarged germinal centers. While we found that *Rgs1* KD did not alter the risk of diabetes in NOD mice, we observed that loss of *Rgs1* reduced the frequency of T~FH~ cells. Furthermore, *Rgs1* KD in T cells was sufficient to modify the migration of B cells. These findings suggest that the effects of *Rgs1* KO on germinal center formation described previously may be caused in part by changes in T~FH~ cell function. In addition, our data suggest that *Rgs1* upregulation is a critical step in the migration of T~FH~ cells that enables cells to downregulate CCR7 signals and to migrate into the follicular area. A link between *Rgs1* expression and T~FH~ cell frequency, a T cell subset implicated in type 1 diabetes, could explain the association of *RGS1* variants with autoimmunity.

RESULTS {#S2}
=======

Generation of Rgs1 knockdown NOD mice {#S3}
-------------------------------------

To study the role of *Rgs1* in autoimmune diabetes, we generated transgenic nonobese diabetic (NOD) mice in which *Rgs1* gene expression can be silenced by RNAi in a doxycycline-dependent manner^[@R21]^. We first validated lentiviral constructs for *Rgs1* KD *in vitro*. Candidate shRNA sequences were cloned into the lentiviral vector pUTG^[@R21],[@R22]^ in which shRNA expression is under the control of a doxycycline-inducible promoter. The vector also contains a constitutively expressed tetracycline-repressor and a green-fluorescent protein (GFP) reporter. We generated an *Rgs1* luciferase reporter where *Rgs1* cDNA is incorporated into the 3' UTR of the *Renilla* luciferase gene. We transfected the *Rgs1* luciferase reporter into HEK293 cells transduced with lentivirus encoding different shRNA sequences against *Rgs1*, and quantified *Renilla* luciferase activity as a measure of gene knockdown. We identified two shRNA sequences that potently inhibited the *Rgs1* luciferase reporter ([Fig. 1a](#F1){ref-type="fig"}). These shRNA sequences were further validated for their ability to silence expression of a FLAG-tagged *Rgs1* construct, as measured by quantitative PCR ([Fig. 1b](#F1){ref-type="fig"}) and western blotting ([Fig. 1c and 1d](#F1){ref-type="fig"}). The selected shRNA sequences were then used to generate two distinct *Rgs1* KD NOD lines by lentiviral transgenesis ([Fig. 1e](#F1){ref-type="fig"} and [supplementary Fig. S1](#SD1){ref-type="supplementary-material"}). Finally, we confirmed that doxycycline treatment (100 µg/ml in the drinking water for two weeks) induced *Rgs1* KD *in vivo* ([Fig. 1f--1h](#F1){ref-type="fig"}, and [supplementary Fig. S1](#SD1){ref-type="supplementary-material"}).

Rgs1 silencing sensitizes T cells to CCR7 ligation {#S4}
--------------------------------------------------

*Rgs1* modulates CCR7 signaling by promoting the conversion of the GTP-activated Gα subunit to a GDP-quiescent form that results in re-assembly of the heterotrimeric G-protein complex^[@R1]^, thus terminating chemokine receptor signaling. Accordingly, *Rgs1* KO was shown to sensitize lymphocytes to CCR7 stimuli^[@R11],[@R12]^. We tested the response of *Rgs1* KD T lymphocytes to CCR7 chemokine ligands in a transwell assay. Consistent with a role for *Rgs1* in diminishing CCR7 signaling, *Rgs1* KD increased T cell migration toward CCL19 ([Fig. 2a](#F2){ref-type="fig"}) and CCL21 ([Fig. 2b](#F2){ref-type="fig"}). The chemotactic response to the CXCR4 ligand CXCL12 was also affected, though only modestly ([Fig. 2c](#F2){ref-type="fig"}). Similar results were obtained with *Rgs1* KD B cells ([Figure 2d](#F2){ref-type="fig"}). These data are consistent with a previous report showing that *Rgs1* KO sensitized T cells to CCR7 and CXCR4 ligation^[@R12]^. We concluded that *Rgs1* KD modifies lymphocyte chemotaxis *in vitro* in a manner consistent with observations made with *Rgs1* KO cells.

Rgs1 KD protects against colitis, but does not change the risk of autoimmune diabetes {#S5}
-------------------------------------------------------------------------------------

A study by Hayday and colleagues reported that T cells derived from *Rgs1* KO mice were less pathogenic than their WT counterparts in an experimental colitis model based on the transfer of CD4^+^CD45RB^high^ T cells into immunodeficient mice^[@R12]^. The authors speculated that the absence of *Rgs1* increases the propensity of CD4^+^ T cells to home to secondary lymphoid organs, reducing their dwell time in the gastrointestinal tract and diminishing colitis severity. To test if *Rgs1* KD would recapitulate this phenotype, we transferred sorted CD4^+^CD45RB^high^ T cells from *Rgs1* KD or WT mice into NOD.SCID recipient mice. The results of this experiment suggested that *Rgs1* KD T cells were less colitogenic than WT cells. Colons were lighter and longer, and histological scores lower in mice transplanted with *Rgs1* KD cells ([supplementary Fig. S2](#SD1){ref-type="supplementary-material"}). With an indication that *Rgs1* KD was able to alter T cell function *in vivo*, we proceeded to ask if *Rgs1* silencing would affect the development of autoimmune diabetes in NOD mice. However, we found no difference in the frequency of spontaneous diabetes between WT and *Rgs1* KD mice, whether treated or not with doxycycline ([Fig. 3a](#F3){ref-type="fig"}). Additionally, diabetes onset was tested by two alternative approaches: by administering cyclophosphamide ([Fig. 3b](#F3){ref-type="fig"}) which is thought to disproportionally deplete the regulatory T cell population, leading to a breakdown in immune regulation^[@R23]^, and by transfer of splenocytes from overtly diabetic *Rgs1* KD mice into immunodeficient NOD.SCID mice ([Fig. 3c](#F3){ref-type="fig"}). Both approaches indicated again that *Rgs1* silencing was insufficient to alter the risk of diabetes in the NOD model.

Rgs1 silencing impacts the differentiation of T follicular helper cells {#S6}
-----------------------------------------------------------------------

To further dissect the role of *Rgs1*, we explored its function within secondary lymphoid organs where *Rgs1* may fine-tune local migratory signals. Reports from *Rgs1* KO mice previously linked loss of *Rgs1* to aberrant splenic architecture, characterized by enlarged germinal centers^[@R9],[@R10]^. This observation was replicated in *Rgs1* KD mice: transgenic mice treated with doxycycline had significantly larger germinal centers after immunization ([Fig. 4a and 4b](#F4){ref-type="fig"}). Accordingly, both the frequency and absolute number of IgD^lo^ B cells was increased by *Rgs1* silencing ([Fig. 4c](#F4){ref-type="fig"}). Although the proportion of proliferating (Ki-67^+^) IgD^lo^ cells was not affected by *Rgs1* KD, transgenic mice harbored more proliferating B cells overall ([Fig. 4d and 4e](#F4){ref-type="fig"}). When we analyzed different T cell populations in lymph nodes collected from immunized mice, we found that the frequency of T~FH~ cells, characterized as CD4^+^PD1^high^CXCR5^high^ cells, was diminished in *Rgs1* KD mice ([Fig. 5a--c](#F5){ref-type="fig"}). Further analysis of the T~FR~ population, the regulatory subpopulation of follicular T cells that expresses the transcription factor *Foxp3*^[@R16]^, suggested that the frequency of T~FR~ cells may be elevated ([Fig. 5d](#F5){ref-type="fig"}), though this difference did not reach statistical significance (p=0.07) and the absolute number of T~FR~ cells was instead decreased by *Rgs1* KD ([Fig. 5e](#F5){ref-type="fig"}) similarly to the number of T~FH~ cells. Although *Rgs1* KD T~FH~ cells were reduced in numbers, they resembled WT T~FH~ cells in their expression of ICOS ([Fig. 5f](#F5){ref-type="fig"}) and Bcl6 ([Fig. 5g](#F5){ref-type="fig"}). Immunohistochemical staining further confirmed that the number of CD4^+^ T cells within germinal centers was reduced in *Rgs1* KD animals ([Fig. 5h](#F5){ref-type="fig"}). Collectively, these data show that *Rgs1* KD modifies germinal center formation, as shown previously, and indicate that loss of *Rgs1* reduces the frequency of follicular T cells.

Rgs1 KD increases B cell migration in a B cell-extrinsic manner {#S7}
---------------------------------------------------------------

Data from the *Rgs1* KO mouse model had demonstrated that *Rgs1*-dependent chemokine signals modify germinal center formation^[@R9]--[@R11]^. The increase in germinal centers in the absence of *Rgs1* had been attributed to a B cell-intrinsic effect. We sought to investigate if this phenotype is also influenced by *Rgs1* function in T lymphocytes. To this end, we transferred B cells from NOD *Raspberry* mice, that express the mRaspberry fluorescent reporter^[@R24]^, into WT or *Rgs1* KD mice. Migration of *Raspberry*^+^ B cells into the spleen was analyzed by flow cytometry four days later. As observed in previous experiments, T~FH~ cell frequency and number was decreased in the spleen of *Rgs1* KD mice ([Fig. 6a and 6b](#F6){ref-type="fig"}). Notably, transferred *Raspberry*^+^ B cells were more numerous in the spleen of *Rgs1* KD recipient animals ([Fig. 6c and 6d](#F6){ref-type="fig"}), suggesting that loss of *Rgs1* leads to active recruitment and/or retention of circulating B cells into secondary lymphoid organs owing to B cell-extrinsic effects.

Rgs1 deficiency in T cells modifies B cell migration {#S8}
----------------------------------------------------

In order to investigate if *Rgs1* KD in T cells alone can influence the migratory behavior of B cells, we co-transferred B and T cells from WT and *Rgs1* KD mice into NOD.SCID mice in all four possible combinations ([supplementary Fig. S3](#SD1){ref-type="supplementary-material"}). Mice reconstituted with *Rgs1* KD T cells had fewer T~FH~ cells ([Fig. 7a and 7b](#F7){ref-type="fig"}) irrespective of the genotype of co-transferred B cells, indicating that the effect of *Rgs1* KD on T~FH~ cell frequency is T cell-intrinsic. The frequency and number of B cells in the spleen of recipient mice was increased in the presence of *Rgs1* KD T cells ([Fig. 7c and 7d](#F7){ref-type="fig"}); in contrast, the frequency and number of CD4^+^ T cells was comparable in all experimental groups ([Fig. 7e](#F7){ref-type="fig"}). These results suggest that *Rgs1* deficiency in T cells is sufficient to modify B cell migration. Collectively, the data indicate that *Rgs1* KD modifies B cell migration through both B cell-intrinsic and T cell-mediated effects.

Rgs1 KD sensitizes T~FH~ cells to CCR7 ligands {#S9}
----------------------------------------------

The reduced frequency of T~FH~ cells in *Rgs1* KD mice could be due to impaired proliferation after immunization. Alternatively, compromised migration into the follicular area may hinder T cell differentiation towards a T~FH~ cell phenotype. We found that *Rgs1* was up-regulated after T cell activation ([supplementary Fig. S4](#SD1){ref-type="supplementary-material"}). However, reduced *Rgs1* expression in transgenic T cells did not affect their proliferation ([supplementary Fig. S4](#SD1){ref-type="supplementary-material"}). To test if *Rgs1* KD had a direct effect on T~FH~ cell migration, CD4^+^ T cells isolated from immunized mice were subjected to a migration assay towards CCL19, CCL21 and CXCL13. T~FH~ cells from WT mice migrated in response to CXCL13 but were irresponsive to CCR7 ligands ([Fig. 8](#F8){ref-type="fig"}). In contrast, we found that *Rgs1* silencing sensitized transgenic T~FH~ cells to CCL19 and CCL21, without affecting migration towards CXCL13. It was shown previously that the expression of CXCR5 is not sufficient for T~FH~ cell migration into the germinal centers^[@R15]^. T~FH~ cells must also down regulate CCR7 signaling to skew chemotactic signals in favor of CXCL13. Our results show that silencing *Rgs1* in T cells potentiates CCR7 responsiveness, a feature that may compromise the differentiation of T~FH~ cells by positioning them outside of their follicular niche.

DISCUSSION {#S10}
==========

In this study, we describe a functional link between *Rgs1* and T~FH~ cells. *Rgs1* had previously been implicated in chemokine receptor signaling in both T and B cells^[@R9]--[@R12]^. In particular, *Rgs1* deletion was shown to modify the migratory behavior of B cells within follicular areas and to increase germinal center formation^[@R9]--[@R11]^. Even the partial loss of *Rgs1* in heterozygous *Rgs1* mutant mice was demonstrated to impact chemokine responses^[@R11]^, and this was confirmed in our experiments with *Rgs1* KD mice. Germinal centers are structured into the so-called dark and light zones^[@R13]^. These zones are functionally distinct, and their organization is strictly dependent on CXCR4 signals that retain centroblasts - dividing B cells undergoing somatic hypermutation - within the dark zone^[@R25]^. In CXCR4-deficient mice, germinal centers lack distinguishable dark and light zones. The cycling of germinal center B cells from the dark to the light zone and back thus requires sequential up- and down-regulation of CXCR4 signals. Expression of CXCR4 itself modifies these signals. In addition, increased *Rgs1* expression is required to desensitize B cells to CXCR4 ligation. Consistent with this notion, germinal centers in *Rgs1* KO mice feature a more prominent dark zone^[@R9]^, likely because GC B cells stay sensitive to CXCL12 even after decreasing CXCR4 expression. Consequently, the abnormal size and structure of germinal centers in *Rgs1* deficient mice had been attributed primarily to a change in B cell chemotaxis. However, *Rgs1* is also expressed in T cells^[@R12]^. *Rgs1* is upregulated following T cell activation, and is expressed at particularly high levels in T~FH~ cells^[@R16]^. T~FH~ cells localize to the follicular areas of secondary lymphoid organs, and participate in germinal center reactions. Their correct localization requires not only up-regulation of CXCR5, that draws T~FH~ cells towards B cell areas, but simultaneous down-regulation of CCR7 signals^[@R15]^. Expression of CXCR5 alone was shown to be insufficient to promote T cell migration into follicles. Notably, CCR7 expression is reduced but not absent in T~FH~ cells^[@R15]^. Furthermore, Kehrl and colleagues have reported that partial loss of CCR7 is insufficient to significantly diminish CCR7-dependent chemotaxis^[@R10]^. *Rgs1* expression may thus serve to further desensitize activated T cells to CCR7 ligands that would otherwise retain them in the T cell zone. We propose that loss of *Rgs1* impairs the migration of activated T cells into the B cell zone and thereby inhibits the full differentiation of T~FH~ cells^[@R26]^. In a situation analogous to *Rgs1* KO B cells being retained in the dark zone by hypersensitivity to CXCL12, *Rgs1* deficient T cells are presumably retained in the T cell zone by hypersensitivity to CCL19 and CCL21. This idea is supported by our observation that *Rgs1* KD T~FH~ cells migrated in response to CCR7 ligation, while WT T~FH~ cell did not. Of note, CCR7 expression itself was not affected by *Rgs1* KD (data not shown). Our data thus indicate that *Rgs1* is a key modifier of T cell localization within lymphoid organs, and that *Rgs1* plays a role in the differentiation of T~FH~ cells.

Interestingly, our data suggest that *Rgs1* silencing in T cells alone had an effect on B cell migration. We posit that the germinal center phenotype described for *Rgs1* KO mice may be exacerbated by a change in T cell function, and that this phenotype is not solely caused by B cell-intrinsic effects. Both previously reported data^[@R9]^ and our own experiments support the notion that loss of *Rgs1* directly affects B cell migration. However, T cells appear to contribute to altered B cell trafficking in *Rgs1* deficient mice. Mice devoid of T~FH~ cells fail to form germinal centers. The observations that loss of *Rgs1* both reduces T~FH~ cell frequency and increases germinal center formation may seem contradictory. This unexpected correlation could be explained first by the fact that the B cell-intrinsic effects of *Rgs1* deficiency are dominant, and second because T~FH~ cells are reduced in number but not entirely absent in *Rgs1* KD mice. *Rgs1* KD had a moderate impact on T~FH~ cells overall, and it will be of interest to revisit *Rgs1*'s role in T~FH~ cells in the context of mice completely deficient in *Rgs1*^[@R9]^. Exactly how and to what extent the loss of *Rgs1* in T cells might contribute to increased germinal center size remains to be explained. Notwithstanding, our findings that *Rgs1* plays a role in T~FH~ cells may provide a possible explanation for the association of *RGS1* with several autoimmune disorders including type 1 diabetes^[@R2]--[@R5]^. T~FH~ cells have been implicated in multiple sclerosis^[@R27],[@R28]^ and type 1 diabetes^[@R17]--[@R19]^. Conceivably, *RGS1* variants that promote T~FH~ cell formation could increase the risk of autoimmunity. In this regard, a disease-associated *RGS1* variant has been associated with elevated levels of CXCL13 in the cerebrospinal fluid of multiple sclerosis patients, thus linking a T~FH~-relevant chemokine to *RGS1* gene variation in the context of autoimmune disease^[@R29]^. Whether an analogous relationship can be found between the type 1 diabetes-associated variants and T~FH~ cell frequency warrants further investigation.

In sum, we have shown that *Rgs1* is a critical modifier of T cell migration within lymphoid tissue, and that this disease-associated gene participates in the development and function of T~FH~ cells. In light of multiple recent publication reporting an association between elevated T~FH~ cell frequency and type 1 diabetes^[@R17]--[@R19]^, our findings raise the intriguing possibility that *RGS1* variation impacts the risk of autoimmunity owing to its role in T~FH~ cells.

MATERIALS AND METHODS {#S11}
=====================

Mice {#S12}
----

Non-obese diabetic (NOD) mice were maintained under specific pathogen-free conditions at the Joslin Diabetes Center. Transgenic mice were generated as described previously^[@R30]^. Briefly, lentiviral vectors encoding a short-hairpin RNA (shRNA) that targets the sequences CGCAAATAACAGTTGCTATTA (\#1) or GCATAACAAAGCAGAGAATAT (\#3) in the *Rgs1* gene were used in which shRNA expression is under the control of a tetracycline-inducible promoter^[@R21]^. The same lentiviral construct also encodes the tetracycline repressor and a GFP reporter, both driven by a constitutive promoter^[@R21]^. Lentiviral particles were microinjected into the perivitelline space of NOD zygotes. Transduced embryos were re-implanted into pseudo-pregnant NOD mice. Transgenic animals were identified by GFP expression, and bred several generations to establish stable lines carrying a hemizygous transgene with Mendelian inheritance. Transgenic mice were treated with 100 µg/ml doxycycline in the drinking water to silence *Rgs1* in all experiments unless specified. Data for shRNA \#1 mice are shown in all experiments, unless otherwise noted. All experiments were approved by the Institutional Committee for the Care and Use of Animals (IACUC) at the Joslin Diabetes Center (protocol \#2014-01).

Luciferase assay {#S13}
----------------

The *Rgs1* cDNA (GenBank: BC028634.1) was cloned into the dual-luciferase reporter plasmid psiCheck2 (Promega). HEK293T cells were transfected using Fugene 6 transfection reagent (Promega) combining 100 ng psiCheck2 plasmid together with 300 ng lentiviral vector pUTG containing a doxycycline-inducible shRNA sequences against *Rgs1*. Luminescence in cell lysates was measured with a SynergyMx luminometer (Biotek) after 48h to assess reporter silencing.

Western blotting {#S14}
----------------

To validate the knockdown efficiency of selected shRNA sequences *in vitro*, HEK293T cells were co-transfected with 1 µg of pcDNA3 plasmid containing the *Rgs1* gene fused to a N-terminus FLAG-tag peptide and 1 µg of pUTG vector containing a shRNA sequence against *Rgs1* transcript. Cell lysates were resolved in a 15% SDS-PAGE and transferred onto a nitrocellulose membrane. Proteins were visualized using the following antibodies: HRP-anti-FLAG antibody (Sigma) and rabbit anti-actin antibody (Santa Cruz Biotech) Endogenous Rgs1 expression in lymphocytes was also analyzed using an anti-rabbit Rgs1 antibody (Thermo Scientific).

Quantitative PCR {#S15}
----------------

RNA isolation was performed using TRIzol reagent (Life Technologies). Subsequently cDNA was synthesized using the Superscript III (Life Technologies) according to manufacturer's protocol. Quantitative *Rgs1* PCR was performed using the following primers: Fwd 5' TTTTCTGCTAGCCCAAAGGA 3' and Rev 5' TGTTTTCACGTCCATTCCAA 3'. Results were normalized to GAPDH.

Lymphocyte migration assays {#S16}
---------------------------

T and B cells were isolated by magnetic sorting using a Pan T cell isolation kit II or a CD43 (Ly48) Microbeads respectively (Miltenyi Biotech). Cell purity following magnetic sorting was \>95% for all experiments. Cells derived from *Rgs1* KD (GFP^+^) and wild type (GFP^−^) mice were mixed in a 1:1 ratio and placed in the upper chamber of transwell plate. In the lower chamber, CCL19, CCL21, CXCL12 or CXCL13 was added to the media at the indicated concentrations. Cells that transmigrated to the lower chamber over the period of 4 hours were analyzed by flow cytometry. Percentage of migration = (number of cells in the lower chamber after migration / input cell number in the upper chamber) × 100.

Diabetes measurements {#S17}
---------------------

Diabetes incidence in transgenic mice was compared to non-transgenic littermates. Four-week old mice were fed 100 µg/ml of doxycycline in drinking water *ad libitum* and were either left to develop diabetes spontaneously over the course of 30 weeks or administered 200 mg/kg cyclophosphamide intraperitoneally to accelerate diabetes onset. In additional experiments, adoptive transfer of diabetes was performed by injecting intravenously 2 × 10^6^ splenocytes from overtly diabetic NOD *Rgs1* KD mice into 6-week old NOD.SCID mice. Cell recipients were then either treated or not with doxycycline. Diabetes was tested by glycosuria measurements using Diastix (Bayer). Mice with two consecutive readings of 250 mg/dl were considered diabetic.

Histology and immunofluorescence {#S18}
--------------------------------

Five days after subcutaneous immunization in the leg with ovalbumin in complete Freund adjuvant (CFA), mice were euthanized and spleen, axillary lymph nodes (ALN) and inguinal lymph nodes (ILN) were dissected and frozen in OCT medium. Sections mounted on slides were stained with the following antibodies: anti-CD45R (B220) Alexa fluor 488 (eBioscience), anti-Ki67 (eBioscience), anti-CD4 (Serotec) or biotinylated peanut agglutinin (PNA) (Sigma), followed by the secondary antibody anti-rat Alexa Fluor 488 or Alexa Fluor-594 streptavidin (Invitrogen), and analyzed by fluorescent microscopy. Germinal centers size was determined using the measuring tool in the CellSense software (Olympus).

Flow cytometry {#S19}
--------------

Lymphocytes were purified from the spleen or lymph nodes of WT and *Rgs1* KD mice and labelled with the following antibodies: anti-PD1 PE-Cy7, anti-CXCR5 APC, anti-CD4 PE, anti-IgD PE, anti-ICOS PE or anti-CD19 PB (BioLegend). Foxp3 intracellular staining kit (eBioscience) was used to label follicular regulatory T cells. Fixation/Permeabilization buffers were used to stain intracellular Bcl6 and Ki-67. Intrinsic GFP and Raspberry fluorophores were also analyzed in specific experiments. Data were acquired on an LSRII flow cytometer (BD Biosciences) and analyzed using the FlowJo software (TreeStar Inc.).

B cell transfer assay {#S20}
---------------------

B cells were isolated from NOD *Raspberry* donors by negative selection using CD43 (Ly-48) magnetic beads (Miltenyi Biotech). Cell purity following magnetic sorting was \> 95%. 2 × 10^7^ cells were injected intravenously into age and gender matched WT or *Rgs1* KD NOD mice. Two weeks later, mice were immunized via intradermal injection in the leg with 160 µg of ovalbumin in complete Freund's adjuvant (CFA). Mice were euthanized for analysis four days later.

Lymphocyte transfer into NOD.SCID mice {#S21}
--------------------------------------

T and B lymphocytes were isolated by magnetic sorting from WT or *Rgs1* KD mice by negative selection using the Pan T cell isolation kit or CD43 (Ly-48) microbeads (Miltenyi Biotech.). WT and *Rgs1* KD T and B cells (each 1 × 10^7^) were mixed at a 1:1 ratio in all four combinations. A total of 2 × 10^7^ cells were injected intravenously into age and gender matched NOD.SCID recipient mice. Two weeks later, mice were immunized as described previously. Mice were euthanized for analysis of lymph nodes and spleens four days later.

Statistical analyses {#S22}
--------------------

Experimental groups were compared by two-tailed unpaired student's t-test using the GraphPad Prism software (Treestar Inc.). A P value \< 0.05 was considered significant. Sufficient sample size was estimated withouth the use of a power calculation. No samples were excluded from the analysis. No randomization was used for animal experiments. Data analysis was not blinded.
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![Generation and validation of NOD Rgs1 KD mice. (**a--d**): HEK293 cells were transduced with lentivirus encoding *Rgs1* shRNA sequence \#1 or \#3 under the control of a doxycycline-inducible promoter. *Rgs1* KD or control cells were transfected with the *Rgs1* luciferase reporter (**a**) or with an expression vector containing a FLAG-tagged version of the RGS1 protein (**b--d**). *Rgs1* knockdown efficiency was then analyzed by luminescence measurement (**a**), quantitative PCR (**b**) or western blotting (**c,d**). Results in **a** through **d** are representative of three experiments.\
(**e**) GFP expression in blood samples from *Rgs1* KD mice. Representative histograms for *Rgs1* KD (white histogram) and WT mice (black histogram) are shown. (**f--h**): Validation of *Rgs1* silencing *in vivo*. Quantitative PCR (**f**) or western blotting (**g,h**) was performed with spleen mRNA or protein, respectively, from individual *Rgs1* KD (white bars) and WT mice (black bars). Rgs1 protein levels were compared in mice treated or not with doxycycline. Results in **f** through **h** derive from 3--5 biological replicates and are representative of two experiments. All results show mean values +/− SEM.](nihms763948f1){#F1}

![Rgs1 KD sensitizes T cells to CCR7 and CXCR4 stimulation. Migration of T cells from the spleen or lymph nodes (**a--c**) or splenic B cells (**d**) from WT (black) and *Rgs1* KD in response to CCL19 (**a**), CCL21 (**b,d**) or CXCL12 (**c,d**). Data represents means ± SEM of 3 biological replicates. \* p \< 0.05, \*\* p \< 0.01 (unpaired t-test).](nihms763948f2){#F2}

![Rgs1 KD does not change the risk of autoimmune diabetes in the NOD model. (**a**) Spontaneous diabetes incidence in WT and *Rgs1* KD mice treated (bottom panel, P=0.26) or not (top panel, P=0.42) with doxycycline continuously from birth (n = 22 mice per group). None of the differences between genotypes or between treated and untreated groups were statistically significant. (**b**) Cyclophosphamide-accelerated diabetes in WT and *Rgs1* KD mice treated with doxycycline for the duration of the experiment (n = 7 mice per group, P=0.18). (**c**) Diabetes in NOD.SCID mice (n = 5 per group, P=0.17) treated or not with doxycycline following transfer of splenocytes from an overtly diabetic *Rgs1* KD NOD mouse not treated with doxycycline.](nihms763948f3){#F3}

![*Rgs1* KD alters germinal center formation. WT and *Rgs1* KD mice were treated with doxycycline and immunized subcutaneously with ovalbumin in CFA. The draining inguinal lymph node (ILN), non-draining axillary lymph nodes (ALN) and spleen were analyzed 4 days later. (**a**) Representative images of germinal centers stained with peanut agglutinin (PNA) in the spleen (top) and ILN (middle) of WT and *Rgs1* KD mice. The bottom panels show co-staining of PNA with B220 to control for specificity of PNA staining in B cell areas. Scale bar: 200 µm. (**b**) Quantification of the area of germinal centers in 3 (spleen) and 5 (ILN) mice per group. (**c,d**) Frequency and absolute number of IgD^lo^ B cells (**c**) and of Ki-67^+^ cells within the IgD^lo^ population (**d**) in immunized mice (n = 5 mice per group). (**e**) Inguinal lymph nodes were stained for PNA and Ki-67 to visualize proliferating B cells within germinal centers. Scale bar: 100 µm. \* p \< 0.05, \*\*\* p \< 0.001 (unpaired t-test).](nihms763948f4){#F4}

![*Rgs1* KD decreases the frequency of T~FH~ cells. Representative flow cytometry results (**a**), frequency (**b**) and number (**c**) of CD4^+^PD-1^+^CXCR5^+^ T~FH~ cells in immunized WT and *Rgs1* KD mice. Cells shown in **a** are gated on the CD4^+^ population. (**d,e**): Representative flow cytometry results (**d**) and frequency (**e**) of FoxP3^+^ expressing cells within the CD4^+^PD-1^+^CXCR5^+^ population gated as shown in **a**. (**f**) Representative flow cytometry results for ICOS expression within the CD4^+^PD-1^+^CXCR5^+^ population as gated in **a**. (**g**) Frequency of CD4^+^CXCR5^+^Bcl6^+^ cells and mean fluorescence intensity (MFI) of Bcl6 staining within this population in immunized WT and *Rgs1* KD mice. (**h**) Spleen sections were stained with PNA and anti-CD4 to quantify CD4^+^ T cells within germinal centers of immunized WT and *Rgs1* KD mice. Representative images and summary data for 5 WT and 3 *Rgs1* KD mice are shown. Results are representative of two or more experiments. All data show means ± SEM, \* p \< 0.05, \*\* p \< 0.01 (unpaired t-test).](nihms763948f5){#F5}

![The migratory behavior of WT B cells is modified in *Rgs1* KD mice. WT NOD *Raspberry* B cells were transferred into WT or *Rgs1* KD mice treated with doxycycline. Recipient mice were immunized, and spleens were analyzed 4 days later. Representative flow cytometry data (**a,c**), frequency and absolute number (**b,d**) of host CD4^+^PD1^high^CXCR5^high^ T cells (**a,b**) and donor WT *Raspberry* B cells (**c,d**). Data show mean values ± SEM in 5 WT and 6 *Rgs1* KD mice. \* p \< 0.05, \*\* p \< 0.01 (unpaired t-test).](nihms763948f6){#F6}

![*Rgs1* KD in T cells is sufficient to modify B cell migration. T cells and B cells from WT and *Rgs1* KD were co-transferred into NOD.SCID mice in all four combinations. Recipient mice were immunized with ovalbumin in CFA, and draining lymph nodes and spleen were analyzed 4 days later. Representative flow cytometry data (**a,c**) used to measure the frequency of CD4^+^CXCR5^+^ T~FH~ cells (**b**), and the frequency and number of CD19^+^ B cells (**d**) and total CD4^+^ T cells (**e**). Data show mean values ± SEM from 4--5 mice per group.](nihms763948f7){#F7}

![*Rgs1* KD increases T~FH~ cell sensitivity to CCR7 but not CXCR5 ligation. CD4^+^ T cells were purified from WT (black bars) and *Rgs1* KD mice (white bars) and subjected to a transwell migration assays towards CCL19 and CCL21 (100 ng/ml, top panel) or CXCL13 (concentration as indicated, bottom panel). After 4 hours incubation, transmigrated cells were labeled for CD4 and CXCR5 and analyzed by FACS. Data show the percentage CD4^+^CXCR5^+^ cells within the CD4^+^ population and represents means ± SEM of 3 biological replicates. \* p \< 0.05, \*\* p \< 0.01 (unpaired t-test).](nihms763948f8){#F8}
